Results 191 to 200 of about 19,912,299 (390)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Establishment and large-scale validation of a three-dimensional tumor model on an array chip for anticancer drug evaluation. [PDF]

Front Pharmacol, 2022
Xiao RR, Jin L, Xie N, Luo P, Gao W, Tu P, Ai X.   +6 more
europepmc   +1 more source

Development and Evaluation of Transdermal Patches containing Carvedilol and Effect of Penetration Enhancer on Drug Release

, 2018
Niharika Lal, Navneet Kumar Verma
openalex   +1 more source

In vivo microfocal computed tomography and micro–magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat [PDF]

, 2010
Michael D. Jones, Charles W. Tran, Guang Li, Walter P. Maksymowych, Ronald F. Zernicke, Michael R. Doschak   +5 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Clinical review considerations of class I PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation. [PDF]

Chin J Cancer Res, 2022
Zou L, Qi Y, Tang L, Du Y, Xiang M, Chen X, Ma J, Yang Z.   +7 more
europepmc   +1 more source

The Evaluation of New Drugs

Journal of Pharmacy and Pharmacology, 1958
L G, GOODWIN, F L, ROSE
openaire   +2 more sources

Evaluation of TBMDR® and XDRA® for the detection of multidrug resistant and pre-extensively drug resistant tuberculosis

, 2022
Eunjin Cho, Sujin Lee, Ji-Young Lim, Dong‐Sik Kim, Namil Kim, Han Oh Park, Jiim Lee, Eun‐Soon Son, Sang Nae Cho, Wah Wah Aung, Jong Seok Lee   +10 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

An Orthotopic Model of Uveal Melanoma in Zebrafish Embryo: A Novel Platform for Drug Evaluation. [PDF]

Biomedicines, 2021
Tobia C, Coltrini D, Ronca R, Loda A, Guerra J, Scalvini E, Semeraro F, Rezzola S.   +7 more
europepmc   +1 more source